Clinical Trial

New research reveals a stark disconnect between clinical views and patient reality in atopic dermatitis, with millions suffering severe, overlooked impacts.

With key studies now complete, Biofrontera's light-based therapy Ameluz could soon offer a new weapon against widespread actinic keratosis and stubborn acne.

A new class of painkillers promises the power of opioids with a far lower risk of addiction. Tris Pharma's cebranopadol could reshape pain management.

NeuroSense adds world-renowned expert Prof. Steven Arnold to its board, a major vote of confidence in its multi-target Alzheimer's drug, PrimeC.

With a major cash infusion and key pipeline milestones, Xilio Therapeutics validates its tumor-activated approach to fighting cancer and extends its runway to 2027.

Positive early human safety data for its lead drug and new candidates for Rett syndrome and MASH signal a pivotal year for ProQR's Axiomer technology.

A new study on a compact, wireless robotic device could democratize access to precision knee surgery, thanks to pioneering work from a rural Missouri surgeon.

With a key FDA meeting set, Trevi Therapeutics pushes its drug Haduvio into late-stage trials, offering hope for millions with no approved treatments.

A new vectorized antibody therapy for ALS, VTx-002, has been granted FDA Fast Track status, accelerating its path to patients battling the disease.

Rani Therapeutics starts Phase 1 trials for an oral obesity drug, challenging the injectable market with a novel delivery system and a dual-action compound.

China approves Aizhida, a novel once-daily ADHD medication. Its unique dual-action formula provides rapid and sustained symptom control, aiming to transform treatment.

A newly validated genetic test accurately predicts melanoma risk, offering a non-invasive alternative to the standard surgical biopsy for many patients.

Azafaros presents its promising drug, nizubaglustat, for untreatable rare neurological disorders, backed by major funding and late-stage clinical trials.

Interim results from the SPARTAN study reveal a novel lateral-oblique SI joint fusion system offers significant pain reduction and improved function.

Palisade Bio's PALI-2108, a drug targeting IBD at its source, secures a key investment, offering hope for a new era of treatment with fewer side effects.

A first-in-class antibody shows a strong safety profile, de-risking development and offering a new, targeted approach for severe autoimmune diseases.

A routine prenatal screen can now detect a virus that causes birth defects, offering a path to prevention and sparking calls to change medical guidelines.

A landmark trial reveals a new drug combination from BeOne Medicines extends life significantly in advanced stomach cancer, poised to become the new standard.

A promising antiviral combination for Long COVID gets a major boost, accelerating its path to a pivotal clinical trial led by top researchers.

A groundbreaking Duke trial combines a novel device to lure cancer cells with targeted immunotherapy, offering real-time tracking and new hope for patients.